Literature DB >> 11164990

Predictive drug allergy testing: an alternative viewpoint.

W J Pichler1.   

Abstract

T- and B-cells recognise drugs when bound as haptens to carrier molecules. Recent studies suggest that drugs might also bind in a non-covalent form to MHC-peptide complexes and T cell receptors, and are thereby able to stimulate T cells. This has, however, only been shown for drug-specific T cell clones. Functional analysis revealed that drug-reactive T cells secrete high amounts of IL-5 and are cytotoxic. Cytotoxicity is mediated by drug-specific CD4(+) and CD8(+) cells and, as revealed by the immunohistochemical analysis of drug-induced exanthems, might be involved in the killing of keratinocytes thus explaining the drug-induced exanthem. Further work is needed to clarify the type and exact location of the rather labile drug binding to MHC and T cell receptors, and to evaluate what drug allergies might be caused by such an unusual presentation and immune stimulation. This new model as well as findings from the analysis of clinical drug allergies may have major implications on how to test and predict the allergenic potential of drugs. A change and expansion of currently performed test procedures is required to predict the allergenic potential of drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11164990     DOI: 10.1016/s0300-483x(00)00399-1

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  3 in total

1.  Fragment-based prediction of skin sensitization using recursive partitioning.

Authors:  Jing Lu; Mingyue Zheng; Yong Wang; Qiancheng Shen; Xiaomin Luo; Hualiang Jiang; Kaixian Chen
Journal:  J Comput Aided Mol Des       Date:  2011-09-20       Impact factor: 3.686

Review 2.  T cells in drug allergy.

Authors:  Werner J Pichler
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.806

Review 3.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.